Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bavarian Nordic ASCHIX:BAVAC 79 Debt-to-Equity is 0.01 as of Mar. 2026, which is 89% below its 10-year median of 0.09. GuruFocus rates CHIX:BAVAC with a GF Score™ of 79/100 and a GF Value™ of kr173.46. The stock has 2 warning signs investors should review. Among 965 Biotechnology companies, Bavarian Nordic AS ranks better than 99.9% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Bavarian Nordic AS's Debt-to-Equity or its related term are showing as below:
CHIX:BAVAc'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.09 Max: 0.98
Current: 0.01
During the past 13 years, the highest Debt-to-Equity Ratio of Bavarian Nordic AS was 0.98. The lowest was 0.01. And the median was 0.09.
CHIX:BAVAc's Debt-to-Equity is ranked better than 99.9% of 965
companies
in the Biotechnology industry
Industry Median: 0.16
vs CHIX:BAVAc: 0.01
Bavarian Nordic AS (CHIX:BAVAc) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Bavarian Nordic AS Debt-to-Equity Related Terms
Bavarian Nordic AS Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Bavarian Nordic AS's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:BAVAC vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Bavarian Nordic AS's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bavarian Nordic AS Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bavarian Nordic AS's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Bavarian Nordic AS's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bavarian Nordic AS (CHIX:BAVAC) has a Debt-to-Equity of 0.01 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Bavarian Nordic AS and its competitors. This is 89% below median its historical median of 0.09. Over the past decade, Bavarian Nordic AS's Debt-to-Equity has ranged from 0.01 to 0.98. According to the industry distribution chart, Bavarian Nordic AS ranks #1 out of 965 companies in the Biotechnology industry, placing it in the top 0.099999999999994%.
Is Bavarian Nordic AS's Debt-to-Equity too high?
Bavarian Nordic AS's current Debt-to-Equity of 0.01 is 89% below median its 10-year median of 0.09. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.98. The Biotechnology industry median Debt-to-Equity is 0.16. Bavarian Nordic AS's value of 0.01 is 93.8% below this industry median. Based on the distribution chart, Bavarian Nordic AS ranks #1 out of 965 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bavarian Nordic AS has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Bavarian Nordic AS's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bavarian Nordic AS ranks #1 out of 965 companies for Debt-to-Equity. This places Bavarian Nordic AS in the top 0% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. Bavarian Nordic AS's value of 0.01 is 93.8% below this benchmark. Historically, Bavarian Nordic AS's own Debt-to-Equity has ranged from 0.01 to 0.98 over the past decade. While the company's 10-year median is 0.09 vs. the industry median of 0.16, Bavarian Nordic AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bavarian Nordic AS's current Debt-to-Equity of 0.01 is 93.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Bavarian Nordic AS and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bavarian Nordic AS's current Debt-to-Equity is 0.01, which is 89% below median its own 10-year median of 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bavarian Nordic AS stock overvalued right now?
Bavarian Nordic AS (CHIX:BAVAC) has a current Debt-to-Equity of 0.01. The stock's GF Value™ is kr173.46, compared to a current price of kr188.30 — trading 8.6% above its estimated fair value. The current Debt-to-Equity is 0.01, which is 89% below median its 10-year median of 0.09 and 93.8% below the Biotechnology industry median of 0.16. Bavarian Nordic AS's overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Bavarian Nordic AS (CHIX:BAVAC), the current Debt-to-Equity is 0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bavarian Nordic AS (CHIX:BAVAC) Overvalued in 2026?
Based on GuruFocus' analysis, Bavarian Nordic AS stock appears to be overvalued.
The current stock price of kr188.30 is trading 8.6% above its estimated GF Value™ of kr173.46.
Key valuation signals for CHIX:BAVAC:
Debt-to-Equity: 0.01 (89% below median its 10-year median of 0.09)
GF Value™: kr173.46 vs. price of kr188.30 (8.6% above fair value)
Industry Position: 93.8% below the Biotechnology median (#1 of 965)
No single metric tells the full story. See the CHIX:BAVAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The group is a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and has a portfolio of travel vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora, VIMKUNYA and Vivotif.
79GF Score
Get the complete analysis for CHIX:BAVAC
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BAVAC has been successfully added to your 
